Skip to main content
Erschienen in: Digestive Diseases and Sciences 4/2018

08.02.2018 | Original Article

Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study

verfasst von: Dejan Micic, Andres Yarur, Alex Gonsalves, Vijaya L. Rao, Susan Broadaway, Russell Cohen, Sushila Dalal, John N. Gaetano, Laura R. Glick, Ayal Hirsch, Joel Pekow, Atsushi Sakuraba, Seth T. Walk, David T. Rubin

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Clostridium difficile is the most commonly isolated stool pathogen in inflammatory bowel disease (IBD). Traditional risk factors for C. difficile may not exist in patients with IBD, and no prior studies have assessed the risk factors for the isolation of C. difficile in both symptomatic and asymptomatic IBD outpatients.

Methods

We prospectively recruited consecutive IBD patients presenting to our outpatient clinic between April 2015 and February 2016. We excluded patients with a diverting ostomy or ileoanal pouch. Demographics, healthcare exposures, medical therapies and disease activity were recorded from medical charts or surveys. A rectal swab was performed from which toxigenic culture and PCR analysis for the presence of toxin and fluorescent PCR ribotyping were performed. The primary outcome of interest was isolation of toxigenic C. difficile.

Results

A total of 190 patients were enrolled in this prospective study including 137 (72%) with Crohn’s disease and 53 (28%) with ulcerative colitis. At the time of enrollment, 69 (36%) had clinically active disease. Sixteen (8.4%) patients had toxigenic C. difficile isolated on rectal swab at enrollment and four (2.1%) patients had non-toxigenic C. difficile cultured. Mixed infection with more than one toxigenic isolate was present in 5/16 (33.3%) individuals. Patients with CD with a toxin positive isolate were more likely to have a history of CDI in the past 12 months (40 vs. 11.02%, p = 0.027) and an emergency department visit in the past 12 weeks (50 vs. 20.63%, p = 0.048). In UC, individuals with isolation of C. difficile were more likely to be hospitalized within the past 12 months (66.6 vs. 8.51%, p = 0.003). C. difficile isolation at the time of presentation was not associated with a subsequent disease relapse over a 6-month period in CD (p = 0.557) or UC (p = 0.131).

Conclusion

Healthcare exposures remain a significant risk factor for C. difficile isolation in the IBD population; however, this was not associated with relapse of disease. Further studies assessing the clinical significance of C. difficile isolation is warranted in IBD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976–983.CrossRefPubMed Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976–983.CrossRefPubMed
2.
Zurück zum Zitat Bartlett JG. Clostridium difficile and inflammatory bowel disease. Gastroenterology. 1981;80:863–865.PubMed Bartlett JG. Clostridium difficile and inflammatory bowel disease. Gastroenterology. 1981;80:863–865.PubMed
4.
Zurück zum Zitat Gryboski JD. Clostridium difficile in inflammatory bowel disease relapse. J Pediatr Gastroenterol Nutr. 1991;13:39–41.CrossRefPubMed Gryboski JD. Clostridium difficile in inflammatory bowel disease relapse. J Pediatr Gastroenterol Nutr. 1991;13:39–41.CrossRefPubMed
5.
Zurück zum Zitat Meyer AM, Ramzan NN, Loftus EV Jr., Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol. 2004;38:772–775.CrossRefPubMed Meyer AM, Ramzan NN, Loftus EV Jr., Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol. 2004;38:772–775.CrossRefPubMed
6.
Zurück zum Zitat Meyers S, Mayer L, Bottone E, Desmond E, Janowitz HD. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology. 1981;80:697–700.PubMed Meyers S, Mayer L, Bottone E, Desmond E, Janowitz HD. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology. 1981;80:697–700.PubMed
7.
Zurück zum Zitat Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16:775–778.CrossRefPubMed Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16:775–778.CrossRefPubMed
8.
Zurück zum Zitat Rolny P, Jarnerot G, Mollby R. Occurrence of Clostridium difficile toxin in inflammatory bowel disease. Scand J Gastroenterol. 1983;18:61–64.CrossRefPubMed Rolny P, Jarnerot G, Mollby R. Occurrence of Clostridium difficile toxin in inflammatory bowel disease. Scand J Gastroenterol. 1983;18:61–64.CrossRefPubMed
9.
Zurück zum Zitat Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology. 1981;80:693–696.PubMed Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology. 1981;80:693–696.PubMed
10.
Zurück zum Zitat Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet (London, England). 2011;377:63–73.CrossRef Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet (London, England). 2011;377:63–73.CrossRef
11.
Zurück zum Zitat Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345–351.CrossRefPubMed Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345–351.CrossRefPubMed
12.
Zurück zum Zitat Rodemann JF, Dubberke ER, Reske KA, da Seo H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339–344.CrossRefPubMed Rodemann JF, Dubberke ER, Reske KA, da Seo H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339–344.CrossRefPubMed
13.
Zurück zum Zitat Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:1443–1450.CrossRefPubMed Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:1443–1450.CrossRefPubMed
14.
Zurück zum Zitat Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–210.CrossRefPubMed Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–210.CrossRefPubMed
15.
Zurück zum Zitat Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;315:514.CrossRef Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;315:514.CrossRef
17.
Zurück zum Zitat Sorg JA, Dineen SS. Laboratory maintenance of Clostridium difficile. Curr Protoc Microbiol. 2009;Chapter 9:Unit9A-1. Sorg JA, Dineen SS. Laboratory maintenance of Clostridium difficile. Curr Protoc Microbiol. 2009;Chapter 9:Unit9A-1.
18.
19.
Zurück zum Zitat Alasmari F, Seiler SM, Hink T, Burnham CA, Dubberke ER. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis. 2014;59:216–222.CrossRefPubMedPubMedCentral Alasmari F, Seiler SM, Hink T, Burnham CA, Dubberke ER. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis. 2014;59:216–222.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Miller MA, Louie T, Mullane K, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013;13:148.CrossRefPubMedPubMedCentral Miller MA, Louie T, Mullane K, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013;13:148.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Shivashankar R, Khanna S, Kammer PP, et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1466–1471.CrossRefPubMed Shivashankar R, Khanna S, Kammer PP, et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1466–1471.CrossRefPubMed
22.
Zurück zum Zitat Rao K, Micic D, Chenoweth E, et al. Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults. J Am Geriatr Soc. 2013;61:1738–1742.CrossRefPubMedPubMedCentral Rao K, Micic D, Chenoweth E, et al. Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults. J Am Geriatr Soc. 2013;61:1738–1742.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Axelrad JE, Joelson A, Nobel YR, et al. Enteric infection in relapse of inflammatory bowel disease: the utility of stool microbial PCR testing. Inflamm Bowel Dis. 2017;23:1034–1039.CrossRefPubMed Axelrad JE, Joelson A, Nobel YR, et al. Enteric infection in relapse of inflammatory bowel disease: the utility of stool microbial PCR testing. Inflamm Bowel Dis. 2017;23:1034–1039.CrossRefPubMed
24.
Zurück zum Zitat Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am J Gastroenterol. 2010;105:2040–2049.CrossRefPubMed Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am J Gastroenterol. 2010;105:2040–2049.CrossRefPubMed
25.
Zurück zum Zitat Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohn’s Colitis. 2009;3:4–7.CrossRef Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohn’s Colitis. 2009;3:4–7.CrossRef
26.
Zurück zum Zitat Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009;104:1162–1169.CrossRefPubMed Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009;104:1162–1169.CrossRefPubMed
27.
Zurück zum Zitat Dorman SA, Liggoria E, Winn WC Jr., Beeken WL. Isolation of Clostridium difficile from patients with inactive Crohn’s disease. Gastroenterology. 1982;82:1348–1351.PubMed Dorman SA, Liggoria E, Winn WC Jr., Beeken WL. Isolation of Clostridium difficile from patients with inactive Crohn’s disease. Gastroenterology. 1982;82:1348–1351.PubMed
28.
Zurück zum Zitat Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN. Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease. Gastroenterology. 2017;153:430–438.CrossRefPubMed Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN. Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease. Gastroenterology. 2017;153:430–438.CrossRefPubMed
29.
Zurück zum Zitat Behroozian AA, Chludzinski JP, Lo ES, et al. Detection of mixed populations of Clostridium difficile from symptomatic patients using capillary-based polymerase chain reaction ribotyping. Infect Control Hosp Epidemiol. 2013;34:961–966.CrossRefPubMedPubMedCentral Behroozian AA, Chludzinski JP, Lo ES, et al. Detection of mixed populations of Clostridium difficile from symptomatic patients using capillary-based polymerase chain reaction ribotyping. Infect Control Hosp Epidemiol. 2013;34:961–966.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Crowther GS, Chilton CH, Todhunter SL, Nicholson S, Freeman J, Wilcox MH. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother. 2015;70:2316–2321.CrossRefPubMed Crowther GS, Chilton CH, Todhunter SL, Nicholson S, Freeman J, Wilcox MH. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother. 2015;70:2316–2321.CrossRefPubMed
31.
Zurück zum Zitat Gracie DJ, Williams CJ, Sood R, et al. Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease. Am J Gastroenterol. 2016;111:541–551.CrossRefPubMed Gracie DJ, Williams CJ, Sood R, et al. Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease. Am J Gastroenterol. 2016;111:541–551.CrossRefPubMed
32.
Zurück zum Zitat Rao K, Higgins PD. Epidemiology, diagnosis, and management of Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1744–1754.CrossRefPubMedPubMedCentral Rao K, Higgins PD. Epidemiology, diagnosis, and management of Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1744–1754.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Shakir FA, Thompson D, Marlar R, Ali T. A novel use of rectal swab to test for Clostridium difficile infection by real-time PCR. Am J Gastroenterol. 2012;107:1444.CrossRefPubMed Shakir FA, Thompson D, Marlar R, Ali T. A novel use of rectal swab to test for Clostridium difficile infection by real-time PCR. Am J Gastroenterol. 2012;107:1444.CrossRefPubMed
34.
Zurück zum Zitat Hughes M, Qazi T, Berg A, et al. Host immune response to Clostridium difficile infection in inflammatory bowel disease patients. Inflamm Bowel Dis. 2016;22:853–861.CrossRefPubMedPubMedCentral Hughes M, Qazi T, Berg A, et al. Host immune response to Clostridium difficile infection in inflammatory bowel disease patients. Inflamm Bowel Dis. 2016;22:853–861.CrossRefPubMedPubMedCentral
Metadaten
Titel
Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study
verfasst von
Dejan Micic
Andres Yarur
Alex Gonsalves
Vijaya L. Rao
Susan Broadaway
Russell Cohen
Sushila Dalal
John N. Gaetano
Laura R. Glick
Ayal Hirsch
Joel Pekow
Atsushi Sakuraba
Seth T. Walk
David T. Rubin
Publikationsdatum
08.02.2018
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-4941-7

Weitere Artikel der Ausgabe 4/2018

Digestive Diseases and Sciences 4/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.